IGI Logo

Salient features of the IPO:

* Anthem Biosciences Ltd. (ABL), is an innovation-driven and technologyfocused Contract Research, Development and Manufacturing Organization (“CRDMO”) with fully integrated operations spanning across drug discovery, development and manufacturing, is coming up with an IPO to raise Rs. 3,395cr which opens on 14th July and closes on 16th July 2025. The price band is Rs. 540 - 570 per share.

* The IPO comprises entirely offer for sale (Rs. 3,395cr). The company will not receive any proceeds from the OFS portion.

* Some of the promoter & promoter group (P&PG) are participating in the OFS and are offloading 5.96 – 6.29cr equity shares. Post-IPO, the P&PG and public shareholders will have 75.03% and 24.97% stake in the company, respectively.

Key competitive strengths:

* Offers comprehensive one-stop service capabilities across the drug life cycle for both small molecules and biologics

* Offers a spectrum of technologically advanced solutions across modalities and manufacturing practices

* Differentiated business model catering to the needs of small pharmaceutical and emerging biotech companies, from discovery to commercial manufacturing

* Wide specialty ingredients portfolio, well positioned to capitalize on the large market opportunity for niche specialty ingredients

* Fully built-out automated manufacturing infrastructure with a consistent regulatory compliance track record

Risk and concerns:

* General slowdown in the global economic activities

*  Risk of failure to develop or manufacture commercially viable drugs

*  Risk of revenue loss from manufacturing services post-patent expiry

*  Risk of foreign currency fluctuation

*  Stringent regulatory requirements

*  Risk of under utilisation of manufacturing facilities

*  Competition

Below are the key highlights of the company:

* The global pharmaceutical industry is projected to grow to USD 2,076.0bn by FY29, and CROs and CDMOs are increasingly combining their services to establish integrated CRDMO business models.

* The Indian CRDMO industry is expected to grow at a CAGR of 13.4% from FY24 to FY29 to reach an estimated value of USD 15.4bn, which outpaces the global industry rate of 9.1% and other markets, although pharma companies are subject to challenges such as cost pressures, low rate of experimental compounds moving to commercialization stage and increased regulatory oversight.

* Incorporated in 2006, ABL is an innovation-driven and technology-focused CRDMO with fully integrated operations spanning across drug discovery, development and manufacturing. ABL is one of the few companies in India with integrated New Chemical Entity (“NCE”) and New Biological Entity (“NBE”) capabilities across drug discovery, development, and commercial manufacturing.

* As a one-stop service provider, it serve a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally. It is one of the youngest Indian CRDMO companies and the fastest Indian CRDMO among the assessed peers to achieve a milestone of Rs. 1,000cr of revenue within 14 years of operations, reaching this milestone in FY21.

For Detailed Report With Disclaimer Visit. https://choicebroking.in/disclaimer

SEBI Registration no.: INZ 000160131